Drug Approval | September 23, 2024
Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Stable profits, low leverage to keep credit profiles comfortable
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Subscribe To Our Newsletter & Stay Updated
